CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CMR with T1 and T2 mappingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D009205 Myocarditis NIH 0.38

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0012819 Myocarditis HPO 0.38

There is one clinical trial.

Clinical Trials


1 IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION

Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy and prognostic relationships in apparently healthy subjects with no known heart disease. A further unknown relates to separation between healthy myocardium and the subclinical disease in several groups of patients with suspected cardiac involvement. Examples include patients with systemic inflammatory conditions, as well as patients with a recent COVID-19 infection.

NCT04444128 Myocarditis Heart Failure Myocardial Fibrosis Diagnostic Test: CMR with T1 and T2 mapping
MeSH:Myocarditis
HPO:Myocarditis

Primary Outcomes

Description: number of deaths

Measure: All-cause mortality

Time: 1 year

Description: number of deaths

Measure: All-cause mortality

Time: 5 years

Secondary Outcomes

Description: Number of participants with events including death due to heart failure and and hospitalisation due to Heart Failure

Measure: Heart Failure Outcome

Time: 1 year and 5 years

Description: Number of participants with death due to myocardial infarction, heart failure, arrhythmia or vascular events (pulmonary embolism, aortic dissection, stroke)

Measure: Cardiovascular Outcome

Time: 1 year and 5 years

Description: Number of participants with documented events including sudden cardiac death, appropriate ICD discharge, sustained VT

Measure: Arrhythmia Outcome

Time: 1 year and 5 years


Related HPO nodes (Using clinical trials)


Protein Mutations 0
SNP 0